文献速递抗栓抗凝管理特殊人群用药治疗药物监测与药物基因组学

III度肥胖患者利伐沙班水平监测的病例分析

Monitoring of rivaroxaban levels in patients with class III obesity.
PubMed 文献 · Am J Health Syst Pharm · 2020-01-01

本文通过2例III度肥胖患者使用利伐沙班并监测抗Xa因子活性的病例,探讨药物水平监测的临床解读困难。例1谷浓度在参考范围内继续治疗,例2谷浓度低于参考范围而换用华法林,两例均未发生血栓栓塞事件。结论指出利伐沙班监测在III度肥胖患者中不标准化且普及有限。

要点

  • III度肥胖患者使用利伐沙班时药物水平监测的临床解读存在不确定性。
  • 利伐沙班谷浓度低于参考范围时,可考虑换用华法林等替代抗凝方案。
  • 利伐沙班水平监测尚未标准化且广泛可及性有限。

核心结论

  • III度肥胖患者利伐沙班水平监测的临床解读存在不确定性,监测不标准化且普及有限。

研究设计与样本

  • 本文报告2例III度肥胖患者使用利伐沙班并监测药物水平的病例,并回顾文献中采用校准抗Xa因子活性测定利伐沙班水平的病例报告。

主要发现

  • 病例1利伐沙班谷浓度在参考范围内,继续治疗。
  • 病例2利伐沙班谷浓度低于参考范围,抗凝治疗换用华法林。
  • 两例患者在开始抗凝治疗后超过1年(分别为15个月和22个月)未观察到血栓栓塞事件。

临床怎么用

  • 对III度肥胖患者使用利伐沙班时,可考虑监测药物水平以辅助临床决策。
  • 当利伐沙班谷浓度低于参考范围时,可评估换用华法林等其他抗凝策略。

局限性

  • 利伐沙班水平监测不标准化且广泛可及性有限。
  • 药物水平超出既定参考范围时的临床解读存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is little evidence to guide the use of direct oral anticoagulants (DOACs) in patients with class III obesity. Clinicians face the dilemma that using DOACs in patients with class III obesity may not provide adequate anticoagulation, while avoiding DOACs may deprive them of a useful therapeutic option. We present 2 cases describing our experience navigating rivaroxaban use in patients with class III obesity and review available case reports of measurement of rivaroxaban levels using a calibrated anti-factor Xa assay. SUMMARY: In patient case 1, the rivaroxaban trough level was within the reference range, and therapy was continued. In patient case 2, the rivaroxaban trough level was below the reference range, and the patient's anticoagulation therapy was switched to warfarin. No thromboembolic events were noted in the 2 patients more than 1 year (15 and 22 months, respectively) after initiation of anticoagulation therapy. Because of the many advantages associated with use of DOACs instead of vitamin K antagonists, further research is critical to enabling clinicians to use DOACs more confidently in a broader population. CONCLUSION: When monitoring rivaroxaban therapy in patients with class III obesity, there is uncertainty regarding clinical interpretation of drug levels that fall outside of established reference ranges, and monitoring is not standardized or widely available. In addition to case reports found in the literature, the presented cases highlight these challenges and differing clinical decisions made when evaluating rivaroxaban levels in patients with class III obesity.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Pahlmeyer L, Huang J. Monitoring of rivaroxaban levels in patients with class III obesity. Am J Health Syst Pharm. 2020. PMID: 32382756. doi:10.1093/ajhp/zxaa096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。